ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA)

Bezeichnung:ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA)

CAS-Nr850649-61-5

Englisch Name:ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA)

CBNumberCB91011068

SummenformelC18H21N5O2

Molgewicht339.39

MOL-Datei850649-61-5.mol

ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA) physikalisch-chemischer Eigenschaften

Schmelzpunkt	127 - 129°C
Siedepunkt	519.2±60.0 °C(Predicted)
Dichte	1.342
Flammpunkt	267.8℃
storage temp.	Refrigerator
Löslichkeit	Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
Aggregatzustand	Solid
pka	9.89±0.20(Predicted)
Farbe	White to Off-White

Sicherheit

S-Sätze:	24/25
RIDADR	3077
HS Code	29335990
Giftige Stoffe Daten	850649-61-5(Hazardous Substances Data)

Gefahreninformationscode (GHS)

ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA) Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Alogliptin is a dipeptidyl-peptidase IV (DPP-4) inhibitor that was approved in Japan in 2010 for treatment of type 2 diabetes, a disease in which insulin resistance and β-cell dysfunction lead to hyperglycemia. As islet function is lost, the severity of insulin resistance increases. The introduction of DPP-4 inhibitors has brought a novel class of insulinotropic agents for the treatment options available to type 2 diabetic patients. The therapeutic potential of glucagon-like peptide 1 (GLP-1), an incretin peptide, for the treatment of type 2 diabetes was realized in the 1990s. The insulinotropic effects of GLP-1 depend closely on glucose concentrations providing the possibility of glucose normalization without the risk of hypoglycemia. GLP-1 has other non-insulinotropic physiological actions that are advantageous. It suppresses glucagon secretion from a cells and slows gastric emptying, which contributes to satiety and to a slower passage and reabsorption of carbohydrates. GLP-1 also contributes to satiety via a central mechanism as a neurotransmitter with effects on the hypothalamus.
Chemische Eigenschaften
White Solid
Originator
Syrrx Inc. (now Takeda San Diego) (Japan)
Verwenden
Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). Antidiabetic agent.
Definition
ChEBI: A piperidine that is 3-methyl-2,4-dioxo-3,4-dihydropyrimidine carrying additional 2-cyanobenzyl and 3-aminopiperidin-1-yl groups at positions 1 and 2 respectively (the R-enantiomer). Used in the form of its benzoate salt for treatment of t pe 2 diabetes.
Trademarks
Nesina
Clinical Use
Dipeptidyl peptidase 4 inhibitor:
Treatment of type 2 diabetes in combination with other therapies
target
DPP-4
Stoffwechsel
Alogliptin does not undergo extensive metabolism. Two minor metabolites were detected following administration of an oral dose of [14C]-alogliptin, N-demethylated alogliptin, M-I (<1% of the parent compound), and N-acetylated alogliptin, M-II (<6% of the parent compound). M-I is an active metabolite and is a highly selective inhibitor of DPP-4 similar to alogliptin; M-II does not display any inhibitory activity towards DPP-4 or other DPP-related enzymes. In vitro data indicate that CYP2D6 and CYP3A4 contribute to the limited metabolism of alogliptin.

ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA) Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

850649-61-5, ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA) Verwandte Suche:

Send Inquriy